Moxifloxacin Ophthalmic
Brand Names: Moxifloxacin Ophthalmic Generic
Methodology & AI Transparency ⓘ
Moxifloxacin Ophthalmic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species * Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections.
- 2 Real-world patient consensus: Zero-PHI community consensus: 94% favorable across 12 logged regimens (Moxifloxacin Ophthalmic Generic).
- 3 Typical cash cost range: Public pharmacy ledger: $70.81 low cash benchmark vs. $173.48 chain retail average ($1.5386/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Moxifloxacin Ophthalmic: pruritus (2.9%), diarrhea (8.1%), nausea (8.2%).
Ask our AI Specialists anything about Moxifloxacin Ophthalmic
Moxifloxacin Ophthalmic Mechanism, CYP450 Pathways & DailyMed Monograph
Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species * Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections.
12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs . Biochemical activity of Moxifloxacin Ophthalmic (NDC 50090-6248) reflects fluoroquinolone antibacterial receptor or enzymatic engagement paired with $1.5386/unit CMS NADAC reference benchmarks.
With 13 hours terminal elimination (Moxifloxacin Ophthalmic SPL) residence kinetics and Consistent 65%–77% gastrointestinal absorption profile for Moxifloxacin Ophthalmic bioavailability, Moxifloxacin Ophthalmic undergoes cytochrome cyp3a4, cyp2d6, cyp2c9 biotransformation with dual hepatorenal elimination and establishes therapeutic activity over cmax attained 2–4 hours post-administration of moxifloxacin ophthalmic.
Standard adult regimens span 5 mg/mL Solution/ Drops, Maintenance adjustment for Moxifloxacin Ophthalmic based on hepatic/renal clearance. Prescribers screen specifically against confirmed ige-mediated allergy or cutaneous reaction to moxifloxacin ophthalmic (moxifloxacin ophthalmic) components; uncompensated hepatic or renal insufficiency incompatible with moxifloxacin ophthalmic (5 mg/ml solution/ drops) clearance, while community micro-logs most frequently note nausea (8.2% of reports), diarrhea (8.1% of reports), headache (5.4% of reports).
Co-prescribing strong CYP3A4 inhibitors or inducers can modify Moxifloxacin Ophthalmic metabolic elimination kinetics.
Reconcile eGFR-adjusted medications before escalating Moxifloxacin Ophthalmic in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Moxifloxacin Ophthalmic (Moxifloxacin Ophthalmic) components
- Uncompensated hepatic or renal insufficiency incompatible with Moxifloxacin Ophthalmic (5 mg/mL Solution/ Drops) clearance
Logged Side-Effect Incidence (12 Reports)
Moxifloxacin Ophthalmic Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Moxifloxacin Ophthalmic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy of skin-applied moxifloxacin on therapeutic laparoscopy-induced wound The results of the current clinical trial demonstrated that the use of applied to the skin MXF could be a potential option to expedite therapeutic laparoscopy-induced wound healing by reducing redness, oedema, ecchymosis, and... BMC surgery • 2025-05-06 • Phase III Randomized Trial | N = 80 | 88/100 | PMID 40329263 ↗ |
| New Insights on Lefamulin real-world benefits and safety in a pooled phase 3 clinical trial: What a 646-Participant Study Found Lefamulin may provide a valuable intravenous/oral single-drug treatment alternative to fluoroquinolones or macrolides for empiric treatment of patients with CABP, including cases of patients at risk for poor outcomes due to... BMC pulmonary medicine • 2021-05-08 • Phase III Randomized Trial | N = 646 | 87/100 | PMID 33964925 ↗ |
| Omadacycline vs. Moxifloxacin: Which Works Better for Adults with community-acquired bacterial pneumonia? Omadacycline was non-inferior to moxifloxacin for IACR at PTE, with high clinical success across pathogen types and patient subgroups. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases • 2021-03-15 • Phase III Randomized Trial | N = 660 | 87/100 | PMID 33484864 ↗ |
| Can This Approach Help? Inside the Latest Research on Applying a Pharmacometrics-Enabled Machine Learning Analysis to Predict 2-Month Four-week time-to-positivity phase 2a data provided more information compared to the 2-week time-to-positivity data for the prediction of culture conversion. Clinical and translational science • 2026-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42576151 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of omadacycline by body mass index in patients The omadacycline fixed-dosing strategy showed consistent safety and real-world benefits in patients with CABP of different body sizes. Respiratory medicine • 2021-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34058682 ↗ |
Moxifloxacin Ophthalmic Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5386/unit (~$46.16/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $173.48 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $70.81 / mo | View logs ↓ |
Moxifloxacin Ophthalmic Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Moxifloxacin Ophthalmic RxNorm Concept ID | 403818 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5386 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $173.48 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $70.81 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Moxifloxacin Ophthalmic Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Moxifloxacin Ophthalmic integrating DailyMed SPL (2023-10-31), CMS NADAC ($1.5386/unit), and 12 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Moxifloxacin Ophthalmic community threads and patient logs by age, biological sex, dosage, and treatment duration.